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Abstract
Background: Adenomatous polyposis coli (Apc) is a large multifunctional protein known to be
important for Wnt/β-catenin signalling, cytoskeletal dynamics, and cell polarity. In the developing
cerebral cortex, Apc is expressed in proliferating cells and its expression increases as cells migrate
to the cortical plate. We examined the consequences of loss of Apc function for the early
development of the cerebral cortex.
Results: We used Emx1Cre to inactivate Apc specifically in proliferating cerebral cortical cells and
their descendents starting from embryonic day 9.5. We observed reduction in the size of the
mutant cerebral cortex, disruption to its organisation, and changes in the molecular identity of its
cells. Loss of Apc leads to a decrease in the size of the proliferative pool, disrupted interkinetic
nuclear migration, and increased apoptosis. β-Catenin, pericentrin, and N-cadherin proteins no
longer adopt their normal high concentration at the apical surface of the cerebral cortical
ventricular zone, indicating that cell polarity is disrupted. Consistent with enhanced Wnt/β-catenin
signalling resulting from loss of Apc we found increased levels of TCF/LEF-dependent transcription
and expression of endogenous Wnt/β-catenin target genes (Axin2 (conductin), Lef1, and c-myc) in the
mutant cerebral cortex. In the Apc mutant cerebral cortex the expression of transcription factors
Foxg1, Pax6, Tbr1, and Tbr2 is drastically reduced compared to normal and many cells ectopically
express Pax3, Wnt1, and Wt1 (but not Wnt2b, Wnt8b, Ptc, Gli1, Mash1, Olig2, or Islet1). This
indicates that loss of Apc function causes cerebral cortical cells to lose their normal identity and
redirect to fates normally found in more posterior-dorsal regions of the central nervous system.
Conclusion: Apc is required for multiple aspects of early cerebral cortical development, including
the regulation of cell number, interkinetic nuclear migration, cell polarity, and cell type specification.
Background
In the mouse, the cerebral cortex develops from anterior
neuroepithelium starting around half-way through gesta-
tion at embryonic day (E)9.5. During its early develop-
ment the cerebral cortex is divided into the ventricular
zone, the subventricular zone, the intermediate zone, and
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the cortical plate. Cortical progenitors have radial proc-
esses that span the depth of the cerebral cortex and have
endfeet at its apical and basal surfaces. Cell division
occurs in the ventricular and subventricular zones and
daughter cells either undergo more cell divisions or exit
the cell cycle and migrate through the intermediate zone
to the cortical plate where they undergo further differenti-
ation and project axons into the intermediate zone. Even-
tually, different regions of the cerebral cortex exhibit
distinct cytoarchitecture and function and it is believed
that the areal expression of secreted morphogens and
transcription factors contribute to setting this up during
development. For reviews of these processes, see [1-5].
APC (Adenomatous polyposis coli) was originally identified
as a tumour suppressor gene mutated in familial adenom-
atous polyposis, an autosomal dominant condition with
predisposition to colorectal cancers [6] and brain tumours
[7]. Mutations in APC have also been linked to a case of
mental retardation [8]. Mutations in Apc  (the murine
homologue of APC) have been linked to intestinal neo-
plasia in mice [9]. Many genes whose dysfunction is asso-
ciated with tumour formation have important functions
in the normal development of the nervous system [10].
Apc is now known to be involved in regulating a variety of
cellular processes, including mitosis, cytoskeletal dynam-
ics, axonogenesis, cell polarity and apoptosis [11-16]. Apc
is central to the Wnt signalling pathway, in which it medi-
ates the destruction of cytoplasmic β-catenin protein [17]
unless the cell receives a Wnt signal resulting in the stabi-
lisation of β-catenin and its translocation to the nucleus,
where it co-operates with TCF/LEF to activate the tran-
scription of target genes. Wnt/β-catenin signalling has
diverse roles in central nervous system development [18].
Given the various functions of Apc, there are many ways
in which Apc might influence the development of cerebral
cortical cells.
It has previously been shown that Apc mRNA is widely
expressed throughout the developing brain. In the cere-
bral cortex, proliferating cells express Apc mRNA and its
expression levels increase as cells migrate to the cortical
plate and differentiate [19]. Apc is known to be a regulator
of β-catenin activity and the levels of β-catenin signalling
change as cells stop dividing and move from the ventricu-
lar zone, through the intermediate zone, and into the cor-
tical plate [20]. These observations raise the possibility
that Apc protein might be important for proliferation
and/or the subsequent differentiation of cells in the cere-
bral cortex. Apc has also been implicated in cerebral corti-
cal development via its interaction with the cytoskeletal
protein Lis1 [21], indicating that Apc has functions not
directly related to Wnt/β-catenin signalling.
In this study we test the hypothesis that Apc is important
for early events in the formation of the cerebral cortex
using a Cre/LoxP strategy. We use a floxed Apc  allele,
Apc580S [22], in which Cre-induced recombination leads to
deletion of Apc exon 14 and a frameshift at codon 580 that
has been shown to disrupt the function of Apc [23]. We
used the Emx1Cre allele [24] to produce this mutation of
Apc specifically in cells of the developing cerebral cortex
starting at E9.5. Cerebral cortex depleted of Apc exhibits
reduced size, a massive disorganisation of cell types, and
a profound alteration in the identity of many of its cells.
These defects coincide with increased levels of nuclear β-
catenin and up-regulation of Wnt/β-catenin target genes
as well as alterations to the organisation of the cytoskele-
ton and cell polarity.
Materials and methods
Animals
Mice harbouring various combinations of the following
alleles were used in this study: Apc580S [22]; Emx1Cre [24];
BAT-gal  [25];  Rosa26R  [26]. Timed matings between
Emx1Cre/CreApc580S/+  or  Emx1Cre/+Apc580S/+  and  Emx1+/
+Apc580S/580S animals were used to generate experimental
embryos with the plug day designated as E0.5. Through-
out this manuscript embryos are designated 'control'
(Emx1Cre/+Apc580S/+) or 'mutant' (Emx1Cre/+Apc580S/580S).
Other genotypes were not used.
Injection of S-phase tracers and estimation of proliferative 
pool and cell cycle kinetics
For estimation of the proliferative pool size, cumulative
bromodeoxyuridine (BrdU) labelling was performed by
injecting BrdU (200 μl of 100 μg/ml (in 0.9% NaCl)
(Sigma St. Louis, MO, USA) intra-peritoneally to pregnant
females every 2 hours over a 12-hour period. Embryos
were collected after 12 hours from the first injection. For
estimation of cell cycle kinetics, double labelling experi-
ments were done by intra-peritoneal injection of iodode-
oxyuridine (IdU; 200 μl of 100 μg/ml in 0.9% NaCl
(Sigma)) and BrdU (200 μl of 100 μg/ml (in 0.9% NaCl)
(Sigma)) 1.5 hours later. Animals were sacrificed 30 min-
utes after BrdU injection following a protocol previously
described [27]. Coronal sections of cerebral cortex were
immunostained for BrdU and IdU and cell cycle parame-
ters were calculated as described [27].
Genotyping
The following pairs of primers were used for PCR genoty-
ing of genomic DNA extracted from biopsies: Apc forward
5'-CACTCAAAACGCTTTTGAGGGTTGAAT-3', reverse
GTTCTGTATCATGGAAAGATAGGTGGT (product size:
226 base-pairs (wild type allele) 314 base-pairs (580S
floxed allele); Emx1 forward 5'-TGGCCCAACTCGGTGT-
TAGG-3', reverse 5'-CCACCAAGGACTCTATGGTG-3'
(product size 260 base-pairs); Cre forward 5'-ACCTGAT-Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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GGACATGTTCAGGGATC-3', reverse 5'-TCCGGTTAT-
TCAACTTGCACCATG-3' (product size 108 base-pairs);
LacZ  forward 5'-CGAAATCCCGAATCTCTATCGTGC-3',
reverse 5'-GATCATCGGTCAGACGATTCATTGG-3' (prod-
uct size 400 base-pairs).
In situ hybridisation
Embryonic heads (E13.5) were submerged in a solution of
4% paraformaldehyde, 0.1% Tween20 in phosphate buff-
ered saline (PBS) pH9.5 for 8 to 20 hours at 4°C on a
rocking platform, embedded in wax, and cut into sections
10 μm thick. In situ hybridisations for Axin2, Lef1, Wnt2b,
Wnt8b,  Gli1, and Ptc  transcripts were performed as
described previously [28] using digoxygenin-labelled
antisense riboprobes.
Immunohistochemistry
Embryonic heads (E13.5 to E15.5), or whole embryos
(E12.5 and earlier) were submerged in a solution of 4%
paraformaldehyde in PBS for 8 to 20 hours at 4°C on a
rocking platform. Heads were either: embedded in wax
and cut into sections 10 μm thick; frozen and cut into sec-
tions 10 μm thick; or embedded in agarose and cut into
vibratome sections 100 μm thick. Wax sections were
dewaxed in xylene and rehydrated through a series of
solutions of descending ethanol concentration to water.
Sections were microwaved to unmask the antigen epitope.
Chromogenic visualization was done with Envision+ Kit
(Dako, Ely, Cambridgeshire, UK). In some cases sections
were counterstained with Harris-haematoxylin (Thermo
Electron Corporation, Cheshire, UK). For immunofluo-
rescence, following incubation with the primary anti-
body, sections were incubated with species-specific
secondary antibodies conjugated to fluorescent molecules
at a 1:200 dilution: goat anti-mouse or goat anti-rabbit
Alexafluor-488 or Alexafluor-568 (Invitrogen, Paisley,
UK). For detection of IdU/BrdU, a mouse anti-BrdU anti-
body that recognises both IdU and BrdU was used (clone
B44, 1:100 in blocking solution; Becton Dickinson
Oxford, UK). Rat anti-BrdU antibody (clone BU1/75,
1:100; Abcam, Cambridge, UK) was used to detect BrdU
but not IdU. In case of double labelling, goat anti-mouse
highly cross-absorbed antibodies were used to prevent
cross-reactivity. Nuclei were counterstained using the
DNA dye TO-PRO-3 iodide (Invitrogen) at 1 μM. Sections
were mounted under coverslips using Mowiol to prevent
fading of fluorescence. The following additional primary
antibodies were used at the dilutions stated: Apc(C-20)
rabbit, sc-896, 1:400 (Santa Cruz Biotechnology, Santa
Cruz, CA, USA) immunohistochemistry on vibratome sec-
tions and dissociated cells); Apc (ab15270), rabbit poly-
clonal, 1:100 (Abcam; immunohistochemistry on wax
sections);  β-catenin, mouse, 610154, 1:200 (BD Bio-
sciences UK, Oxford, UK) beta-III-tubulin, mouse, Tuj1,
1:800 (Sigma); P21, rabbit, SX118, 1:100 (BD Bio-
sciences); Pax3, mouse, Pax3, 1:400 (DSHB, University of
Iowa, Iowa City, USA); Foxg1, rabbit rabbit polyclonal
antibody described in [29], 1:500; C-myc, mouse, 9E10,
1:200 (Roche Diagnostics GmbH, Mannheim, Germany);
phosphohistone H3 (PH3), rabbit, H9908, 1:400
(Sigma); WT1, mouse, 6F-H2, 1:1000 (Dako); N-cad-
herin, mouse, 610920, 1:200 (BD Biosciences); Pericen-
trin, rabbit, PRB-432C, 1:400 (Covance Emeryville, CA,
USA); Tbr1 and Tbr2, rabbit polyclonal antibodies
described in [30], 1:500; Olig2, rabbit polyclonal anti-
bodies described in [31], 1:10,000; Mash1 mouse mono-
clonal 24B7.2d11, 1:100 (BD Biosciences); Islet1, mouse
40.2D6, 1:100 (DSHB); Pax6, mouse, Pax6, 1:400
(DSHB).  
Staining for bacterial LacZ (β-galactosidase)
Embryos were dissected in ice cold PBS and fixed with
shaking at 4°C for 1 hour in LacZ fixative (PBS contain-
ing: paraformaldehyde (4%); NP40 (0.02%), sodium
deoxycholate (0.01%); EGTA (5 mM); and MgCl2 (2
mM)). LacZ staining was as described previously [25].
Detection of apoptosis by TUNEL
To detect apoptotic cells, terminal deoxynucleotidyl nick
end labelling (TUNEL) was performed according to the
supplier's protocol (Roche). Total numbers of TUNEL
positive cells were counted in sections of E13.5 control
and mutant embryos.
Primary cell culture and FACS analysis
The telencephalon was isolated and dissected in ice-cold
oxygenated Earle's buffered salts solution. The cerebral
cortex was separated from the ventral telencephalon. Tel-
encephalic tissue was dissociated using Papain dissocia-
tion system kit (Worthington Biochemical Corporation,
Lakewood, NJ, USA) according to the supplier's protocol.
Cells were resuspended in serum-free medium. Dissoci-
ated cells were then either: embedded in collagen [32] and
cultured for 4 hours, after which time they were fixed and
processed for Apc immunohistochemistry; or subjected to
fluorescence activated cell scanning (FACS) analysis fol-
lowing fixation in -20°C 70% ethanol for ≥ 2 hours on ice
and resuspension in PBS containing 0.05 mg/ml of pro-
pidium iodide (Sigma) and 0.5 mg/ml of RNAseA
(Roche). FACS analysis was performed on FACSCalibur
(BD Biosciences), which runs CellQuest software.
Microscopy
Slides were photographed using a Leica DMLB upright
compound microscope connected to a Leica DSC480 dig-
ital camera with Leica IM50 image management software.
Fluorescent staining was imaged using a Leica TCS NT
confocal system with associated software. Alexafluor-488
staining was collected in the FITC (green) channel, Alex-Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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afluor-568 in the TRITC (red) channel and TO-PRO-3 in
the Cy3 (far-red, pseudo-coloured blue) channel.
Statistical analysis and graph plotting
Sigmastat (Systat Software Inc., Richmond, CA, USA) was
used for data analysis. Excel (Microsoft) was used to plot
data.
cDNA synthesis and quantitative reverse transcriptase 
PCR
RNA was extracted from the cerebral cortical tissue at
E12.5, E13.5, and E15.5 using RNEasy mini kit (Qiagen,
Crawley, Sussex, UK) followed by treatment with DNAse
(Roche) to eliminate genomic DNA. The SuperScript III
First-Strand Synthesis SuperMix kit (Invitrogen) was used
to synthesize cDNA from RNA samples. The procedure
was performed according to the supplier's protocol using
random hexamers. The following primers were used for
quantitative reverse transcriptase PCR (qRT-PCR): Apc
exon 4 forward 5'-CCGTTCAGGAGAATGCAGTC-3',
reverse 5'-TGCCGTCTTGTCATGTCTGT-3'; Apc  exon 14
forward 5'-GTGTCCAGCTTGATAGCTAC-3', reverse 5'-
CAAGGCTTCCTGGTCTTTAG-3'; Wnt1 forward 5'-ATAC-
GACCCCGTTTCTGCTG-3', reverse 5'-TTCCACTCCCT-
CACCTCAAAGC-3';  Axin2  forward 5'-
ACAGTAGCGTAGATGGAGTC-3', reverse 5'-CTGT-
GGAACCTGCTGCCTTC-3'; Wnt8b forward 5'-AAGGCT-
TACCTGGTCTACTC-3', reverse 5'-
CAGAGCTGATGGCGTGCACA-3';  GAPDH  5'-GGGTGT-
GAACCACGAGAAAT-3' and 5'-CCTTCCACAAT-
GCCAAAGTT-3'. qRT-PCR was performed using Qiagen
Quantitect SYBR green PCR kit and a DNA Engine Opti-
con continuous fluorescence detector (Genetic Research
Instrumentation, Rayne, Essex, UK) The abundance of
each transcript in the original RNA sample was extrapo-
lated from PCR reaction kinetics using Opticon software.
Transcript levels are expressed relative to GAPDH.
Results
Apc expression in developing wild-type and mutant 
cerebral cortex
During normal development, Apc  mRNA is expressed
throughout the cerebral cortex, with the highest levels of
expression in post-mitotic cells that have migrated from
the ventricular zone [19]. Here we extended this study by
examining the distribution of Apc protein using immuno-
histochemistry. Apc is widely expressed in the forebrain,
with particularly high levels in the cerebral cortex (Figure
1A, D, F, I). As development proceeds from E11.5 to
E14.5, Apc is expressed throughout the proliferative ven-
tricular zone from its apical surface. At E11.5, Apc expres-
sion is particularly prominent at the apical surface of the
ventricular zone (Figure 1B) with a few high expressing
cells populating the basal surface. As cerebral cortex devel-
opment proceeds from E12.5 to E14.5, Apc continues to
be expressed in the ventricular zone but the highest levels
of expression are now seen in post-mitotic cells in the cor-
tical plate (Figure 1E, G, J) and in the intermediate zone,
which contains cells migrating to the cortical plate and
axons projected by post-mitotic cortical plate cells after
E13.5 (Figure 1J). qRT-PCR results show that there is a
dramatic increase in the levels of Apc transcripts between
E12.5 and E15.5 (Figure 1P). This increase coincides with
the increasing proportion of high-expressing post-mitotic
neurons present in the cerebral cortex with increasing age.
We used Cre recombinase driven by the endogenous Emx1
promoter [24,33] to inactivate Apc  expression from a
floxed Apc allele in neural cells in the developing cerebral
cortex starting at E9.5 when the cerebral cortex is starting
to form. LacZ staining of embryos harbouring Emx1Cre and
R26R  reporter alleles[26] confirms the ability of Cre
recombinase to recombine the floxed-stop LacZ reporter
allele in the cerebral cortex of these embryos (Figure 1Q,
R). Emx1 is not expressed in the most dorsal medial telen-
cephalon (the cortical hem region) [33,34] and this
region escapes Cre-mediated recombination (Figure 1Q,
R). The efficiency of Cre recombination (judged from the
intensity of LacZ staining) appears to diminish towards
the lateral edges of the cerebral cortex (Figure 1Q, R) and,
for this reason, we concentrated our subsequent analysis
of the Apc mutant phenotype on the central portion of the
cerebral cortex. We used the Apc580S allele in which exon
14 of Apc is flanked by LoxP sites [22]. Transcripts pro-
duced from the Apc580S  allele following Cre-mediated
recombination lack exon 14, causing a frameshift, and
translation of these transcripts is predicted to produce
non-functional Apc. In order to confirm that Apc levels
were reduced in the cerebral cortex of our mutant, we per-
formed qRT-PCR using primers to exon 4 (present in tran-
scripts produced from the floxed Apc both before and after
Cre-mediated recombination) and exon 14 (only present
in transcripts produced from un-recombined Apc) on RNA
extracted from dorsal telencephalon of control and
mutant embryos at E12.5, E13.5, and E15.5. The ratio of
Apc transcripts containing exon 14 to those containing
exon 4 provides a measure of the efficiency with which
wild-type Apc transcripts were eliminated from the mutant
cortex. At all ages examined we found that the exon
14:exon 4 ratio was reduced in the mutant compared to
the controls (Figure 1S), indicating successful reduction in
the levels of wild-type Apc transcripts in the mutant. The
low levels of wild-type transcripts in RNA samples from
the mutant cortex might reflect subpopulations of cells
within the cerebral cortex that escaped recombination in
the mutant (for example blood vessels) and/or persistence
of wild-type Apc  transcripts after recombination of the
genomic locus. Comparison of Apc immunofluorescence
on sections and collagen-embedded dissociated cells from
control (Figure 1B, E, G, J, L) and mutant (Figure 1C, H,Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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Figure 1 (see legend on next page)
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K, M) cerebral cortex showed that the intensity of immu-
nostaining was much lower in the mutant cells, indicating
successful depletion of Apc protein. The intense spots of
Apc staining in Figure 1H, K correspond to non-specific
staining of blood vessels by the fluorescent secondary
antibody (blood vessels are strongly stained in controls
reacted with the fluorescent secondary antibody alone;
Figure 1N, O). Apc immunohistochemistry on dissociated
cells indicates that some cells in the mutant cerebral cor-
tex retain Apc protein, albeit at reduced levels to that seen
in control cerebral cortex (compare Figure 1L to 1M). In
summary, mutant embryos are unable to express Apc
mRNA or Apc protein at the same levels as their wild-type
counterparts and do not upregulate Apc/Apc expression as
occurs during normal cerebral cortical development.
Neuronal differentiation is disrupted when Apc is lost from 
cerebral cortex
Apc is a multifunctional protein with potential roles in
several aspects of cerebral cortical development. We first
set out to determine the consequence of loss of Apc func-
tion on the organisation and proliferation of cerebral cor-
tical cells. β-Tubulin III (Tuj1) is a neural form of β-
tubulin, which is expressed by post-mitotic neurons [35].
β-Tubulin immunostaining of control and mutant cere-
bral cortex at E12.5 and E13.5 revealed that the mutant
cerebral cortex is disorganised. In controls, β-tubulin is
located in post-mitotic cells in the cortical plate (Figure
2A, C, E, G). In mutants there are β-tubulin stained cells
in the cortical plate but stained cells are also found in
close proximity to the ventricle (Figure 2B, D, F, H). These
results show that while depleting Apc in developing cere-
bral cortex does not prevent the production of post-
mitotic neurons, it does disrupt their ability to occupy
their normal location in the developing cortical plate. This
could reflect precocious differentiation, defective radial
migration, or a combination of the two.
Loss of Apc leads to a reduction in the proliferative pool
The small size of the mutant cerebral cortex prompted us
to ask whether there was a defect in proliferation. Contin-
uous cumulative injection of the thymidine analogue
BrdU labels all cells that are undergoing S-phase during
the pulse [36].
Immunostaining of the cerebral cortex of E13.5 embryos
continuously labelled with BrdU for 12 hours revealed
that the cerebral cortex of the mutant contains a larger
proportion of cells that have not incorporated BrdU than
the control (compare Figure 3A, B to 3C, D). Quantifica-
tion of the relative size of the BrdU-incorporating popula-
tion disclosed a significant reduction of BrdU positive
cells in the mutant cerebral cortex compared to the con-
trol (Figure 3E). A similar result was obtained for E12.5
(not shown). This reduction in the size of the proliferative
pool could reflect alterations in the length of the phases of
Apc/Apc expression in the cerebral cortex during normal development and following Cre-mediated deletion of Apc Figure 1 (see previous page)
Apc/Apc expression in the cerebral cortex during normal development and following Cre-mediated deletion of 
Apc. (A, D, F, I) Immunohistochemistry showing Apc expression in the developing forebrain of control embryos at embry-
onic day (E)11.5 (A), E12.5 (D), E13.5 (F), and E14.5 (I). (B, E, G, J) Higher power magnification of the control cerebral cortex. 
(B) At E11.5, Apc is expressed throughout the cerebral cortex (cc) with prominent expression at its apical (a) surface com-
pared to the basal (b) surface. (E) At E12.5, Apc is expressed throughout the cerebral cortex in the ventricular zone (vz) and 
the newly formed cortical plate (cp) where its expression levels are highest. (G, J) At E13.5 (G) and E14.5 (J), Apc is expressed 
throughout the cerebral cortex c. Apc expression extends from the apical surface of the ventricular zone to the pial edge with 
the highest levels of expression in the cortical plate and intermediate zone (iz). (C, H, K) Apc expression is reduced in the 
cerebral cortex of mutant embryos compared to controls at E11.5 (C), E13.5 (H) and E14.5 (K). The white dotted lines demar-
cate the mutant cerebral cortex. (L, M) Apc immunocytochemistry of dissociated E13.5 control (L) and mutant (M) cells 
showing that Apc expression is reduced in the mutant. Nuclei stained red with Propidium (PI). (N, O) Controls showing that 
the secondary antibody used to detect Apc does not stain neural cells at E12.5 (N) and E13.5 (O), although blood vessels 
(arrows) are strongly fluorescent. (P)Apc transcript levels increase during normal corticogenesis from E12.5 to E13.5 and 
E13.5 to E15.5. Histogram shows levels of Apc relative to GAPDH in mRNA extracted from cerebral cortex at E12.5, E13.5 
and E15.5. Black bars are control and white bars are mutant. Student's t-test p-values are indicated above the bars (comparison 
between all groups ANOVA p = 0.002). (Q, R) LacZ staining (blue) of E12.5 (Q) and E16.5 (R) Emx1Cre/+; R26R forebrain, con-
firming the ability of Cre recombinase to recombine a floxed R26R reporter allele and turn on LacZ expression in the cerebral 
cortex. (S) Mutant cerebral cortex has significantly reduced levels of wild-type Apc transcripts compared to controls. Histo-
gram shows the ratio of transcripts containing exon 14 (deleted following Cre-mediated recombination of Apc580S allele) to 
exon 4 at E12.5, E13.5, and E15.5. Student's t-test p-values are indicated above the bars (comparison between all groups 
ANOVA p = 0.001). There is no significant difference in the ratio obtained from control embryos at the ages examined 
(ANOVA p = 0.390). (D, E, I, J, K, O) Vibratome sections; (A-C, F-H, N) wax sections; (L, M) dissociated cells embedded in 
collagen. Additional abbreviations: h, hippocampus; t, thalamus; vtel, ventral telencephalon. All sections are coronal and dorsal 
is up. Scale bars: (A, D, F, I) 200 μm; (B, C, E, G, H, J, K, N, O) 50 μm; (L, M) 25 μm. Error bars in (P, S) are standard error of 
the mean.Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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the cell cycle, so we investigated these parameters using
the two nucleotide analogues BrdU and IdU [27]. This
technique allows us to determine both Tc (cell cycle
length) and Ts (S-phase length) from a single experiment.
This showed that although the number of proliferating
cells is lower in mutant brains, there is no significant dif-
ference in the length of either the cell cycle (Figure 3F) or
S-phase (Figure 3G) between mutant and control embryos
in the poliferating cells that remain. We used FACS analy-
sis to determine the proportion of proliferating cells that
were in the G0/G1, S, or G2/M stages of the cell cycle. Cell
sorting was performed on dissociated cells taken from
E13.5 control and mutant cerebral cortex and stained with
the DNA binding dye propidium iodide to generate histo-
grams of DNA content (example shown in Figure 3H).
These histograms were used to calculate the cell popula-
tions in different phases of the cell cycle. The S and G2/M
populations in the mutant were reduced to 50% of num-
bers in control embryos (Figure 3I). There was a corre-
sponding increase in the size of the G0/G1 population in
the mutant (Figure 3I). Loss of Apc therefore reduces the
number of proliferating cells by about three-fold but does
not significantly affect the cell-cycle kinetics of the
remaining proliferating cells. The reduction in the size of
the proliferative pool could be caused by cell-cycle arrest,
premature differentiation, or death.
Loss of Apc causes increased apoptosis
The reduced size of the mutant cortex could be contrib-
uted to by increased apoptosis and we next examined this
possibility. Both pro-apoptotic and anti-apoptotic activi-
ties of Apc mutations have been described [37-39]. Inves-
tigation of apoptosis by TUNEL staining revealed that
whereas there are very few apoptotic cells detected in the
control cerebral cortex at E13.5 (Figure 4A, B), there are
many apoptotic cells detected in the cerebral cortex of the
mutant at this stage (Figure 4C, D). Counts of apoptotic
cells in sections of cerebral cortex confirmed a massive
and significant increase in cell death in the mutant com-
pared to the control cerebral cortex (Figure 4E).
Disruption to spatial organisation of the cell cycle and cell 
polarity
During normal cerebral cortical development, neural pro-
genitors undergo interkinetic nuclear migration during
the cell cycle such that cell nuclei undergo mitosis (M-
phase) when they are located at the ventricular surface
and then move deeper into the ventricular zone where
they perform DNA synthesis (S-phase) (for example, see
[40]). PH3 is a M-phase specific protein [41], which
allows us to identify cells that are undergoing mitosis.
PH3 immunostaining of control cerebral cortex at E12.5,
E13.5, and E15.5 (Figure 5A, B, E, F, I, J) shows most
Immunostaining for beta-tubulin III (Tuj1) at embryonic day (E)12.5 and E13.5 in the cerebral cortex of control and mutant  embryos Figure 2
Immunostaining for beta-tubulin III (Tuj1) at embryonic day (E)12.5 and E13.5 in the cerebral cortex of con-
trol and mutant embryos. (A, B, E, F) E12.5. (A, E) At E12.5, Tuj1 staining is restricted to cells of the preplate of the con-
trol cerebral cortex. (B, F) The mutant has a broader Tuj1 expression pattern with positive cells located in the ventricular 
surface (F, black arrow). (C, D, G, H) There is a similar staining pattern at E13.5. (C, G) The control has Tuj1 positive cell in 
the preplate only whereas (D, H) the mutant has more Tuj1 staining with positive cells located in at the ventricular surface (H, 
black arrow). Boxed areas in (A-D) are shown at higher magnification in (E-H). All sections are coronal and dorsal is up. Scale 
bars: (A, B) 200 μm; (C, D) 400 Mm; (E-H) 50 μm.
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Reduced proliferative pool in mutant embryos compared to the control at embryonic day (E)13.5 Figure 3
Reduced proliferative pool in mutant embryos compared to the control at embryonic day (E)13.5. (A-D) Con-
trol (A, B) or mutant embryos (C, D) were pulsed with bromodeoxyuridine (BrdU) for 12 hours to label all cells that had 
passed through S-phase during the pulse. (A, C) Low power images with boxed areas indicating location of higher magnification 
(B, D) images. (E) Quantification of the proportion of BrdU-positive cells as a proportion of total cells. The proportion of 
BrdU-positive cells is significantly lower in the mutant. (F, G) There are no significant differences in cell cycle (F) or S-phase 
(G) length between mutant and control embyos. (H, I) FACS analysis of DNA content of E13.5 control and mutant cerebral 
cortical cells. (H) A histogram of dissociated cells from control cerebral cortex indicating populations in G0/G1, S, and M-
phases of the cell cycle sorted by their DNA content. (I) The proportion of cells in each phase of the cell cycle, calculated from 
histograms like those shown in (H), in control and mutant cerebral cortex. The mutant has significantly more cells in G0/G1 
and significantly fewer cells in S/G2 than the mutant, consistent with a reduction in the population of proliferating cells. All sec-
tions are coronal and dorsal is up. Scale bars: (A, C) 400 μm; (B, D) 50 μm. Error bars in (E, F, G, I) are standard error of the 
mean with Student's t-test p-values for control versus mutant comparison indicated above bars.
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mitotic cells lining up along the ventricular surface. In
contrast, in mutants over the same age range (Figure 5C,
D, G, H, K, L) nearly all the PH3 expressing cells are found
away from the ventricular surface. We examined the loca-
tion of cells in S-phase by BrdU incorporation. In control
embryos, BrdU-positive cells are located in the basal part
of the ventricular zone (Figure 5M, N), whereas BrdU-pos-
itive cells in the mutant lose this distribution and are scat-
tered throughout the ventricular zone (Figure 5O, P; white
arrows indicate BrdU-positive cells located at the mutant
ventricular surface). These results show that loss of Apc
function disrupts the normal cell-cycle stage-specific api-
cal/basal distribution of cerebral cortical progenitor
nuclei
The disturbed apical/basal distribution of cell cycle phases
prompted us to ask if other aspects of cell polarity were
defective. During normal development, cells in the ven-
tricular zone exhibit a polarised distribution of β-catenin,
with the highest concentration found at the apical surface
(Figure 6A, arrows). The centrosome-associated protein
pericentrin [42] is also concentrated at the apical surface
(Figure 6C, arrows). Following loss of Apc, this polarised
distribution is lost, with β-catenin (Figure 6B) and peri-
centrin (Figure 6D) both being more evenly distributed
throughout the cerebral cortex. In the control cerebral cor-
tex the cell adhesion protein N-cadherin is found around
the cell membrane, with particularly intense staining seen
at the apical surface of the ventricular zone (Figure 6E). In
the mutant the N-cadherin staining is much weaker at the
cell membrane and distributed in scattered patches at the
apical surface of the cerebral cortical ventricular zone (Fig-
ure 6F). Overall, proteins normally concentrated at the
apical surface in the control become more diffusely dis-
tributed in the mutant, consistent with a disruption to the
normal mechanisms that maintain apical polarity.
β-Catenin is disregulated following loss of Apc
Apc participates in a cytoplasmic protein complex with β-
catenin that mediates its destruction in the absence of a
Wnt signal. Loss of Apc might, therefore, be expected to
result in increased levels of β-catenin but could also have
other consequences for its cellular localisation. In the con-
trol cerebral cortex, β-catenin protein is concentrated at
Apoptosis in the cerebral cortex is increased in mutant embryos at embryonic day (E)13.5 Figure 4
Apoptosis in the cerebral cortex is increased in mutant embryos at embryonic day (E)13.5. (A, B) A few apop-
totic cells were detected by TUNEL staining in the control. (B) A higher magnification of the boxed area in (A) with white 
arrow indicating TUNEL+ cell (green staining). (C, D) Examples of the mutant showing increased apoptosis in the cerebral cor-
tex (E) Quantification of apoptotic nuclei in sections of control and mutant cerebral cortex shows a large increase in apoptosis 
in the mutant. Student's t-test p-values are indicated above bars. Error bars are standard error of the mean. All sections are 
coronal and dorsal is up. Scale bars: (A, C) 400 μm; (B) 50 μm; (D) 200 μm.
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the cell surface, with particularly high levels apparent at
the apical surface of the ventricular zone. This distribution
is apparent throughout early corticogenesis from E10.5 to
E13.5 (Figure 7A, B, D, E, G, I, J). In the mutant, β-catenin
accumulates in the nucleus. This is first apparent at E10.5
(Figure 7C) and becomes more pronounced at E12.5 (Fig-
ure 7F, H) and E13.5 (Figure 7K). These results show that,
in the mutant, nuclear β-catenin levels exceed those nor-
mally found in the developing cerebral cortex.
Disrupted interkinetic  nuclear  migration in mutant cerebral cortex progenitor cells Figure 5
Disrupted interkinetic  nuclear  migration in mutant cerebral cortex progenitor cells. (A-L) Immunostaining for 
phosphohistoneH3 (PH3; brown) in the telencephalon of control and mutant embryos at embryonic day (E)12.5, E13.5 and 
E15.5. At E12.5, most of the PH3-positive cells in the control cerebral cortex are located at the ventricular surface (B). Most 
PH3-positive cells do not touch the ventricular surface of the mutant (D). At E13.5, the control has most of the PH3-positive 
cells at the ventricular surface (F), but most PH3-positive cells in the mutant are located away from the ventricular surface (H). 
At E15.5, the control has PH3-positive cells on the ventricular surface and singular cells in the ventricular zone and subven-
tricular zone (J), while expression of PH3 in the mutant is decreased and positive cells are scattered in the cerebral cortex (L). 
Blue staining is counterstaining with haematoxylin. (B, D, F, H, J, L) Higher magnification images of the boxed areas in (A, C, E, 
G, I, K), respectively. (M-P) Bromodeoxyuridine (BrdU) incorporation in embryos sacrificed immediately after a 30 minute 
pulse of BrdU labels cells in S-phase. In controls (M, N), BrdU labelled cells are all located away from the ventricular surface 
whereas in the mutant (O, P) many BrdU positive cells are located at the ventricular surface. (N, P) Higher magnification 
images of the boxed areas in (M, O), respectively. All sections are coronal and dorsal is up. Scale bars: (A, C, M, O) 200 μm; (B, 
D) 25 μm; (E, G, I, K) 400 μm; (F, H, N, P) 50 μm.
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Loss of cell polarity in mutant compared to control embryos at embryonic day (E)12.5 Figure 6
Loss of cell polarity in mutant compared to control embryos at embryonic day (E)12.5. (A, B) β-Catenin, (C, D) 
pericentrin, and (E, F) N-cadherin immunostaining (green) in control (A, C, E) and mutant embryos (B, D, F). Red arrows in 
(A, C) point to high levels of β-catenin and pericentrin, respectively, at the apical surface of the ventricular zone in control 
embryos; in the mutant (B, D) the apical localisation of both proteins is lost. (E) In controls, N-cadherin is distributed around 
cells, with particularly large amounts seen at the apical surface (red arrows); in the mutant (F) this pattern is altered, with many 
cells exhibiting much lower (in some cases undetectable) levels of N-cadherin. All sections are coronal and dorsal is up. Scale 
bars: (A-D) 100 μm; (E, F) 20 μm.
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(A-K) Progression of nuclear β-catenin (green) accumulation in the telencephalon of control (A, B, D, E, G, I, J) and mutant (C,  F, H, K) embryos at embryonic day (E) 10.5 (A-C), E12.5 (D-H), and E13.5(I-K) Figure 7
(A-K) Progression of nuclear β-catenin (green) accumulation in the telencephalon of control (A, B, D, E, G, I, J) 
and mutant (C, F, H, K) embryos at embryonic day (E) 10.5 (A-C), E12.5 (D-H), and E13.5(I-K). (A, D, I) In the 
control, β-catenin staining is widespread throughout the cerebral cortex (B, E, G, J) Higher magnification images show that β-
catenin is predominantly located at the cell surface and excluded from the nucleus. In contrast, the mutant has significant num-
bers of cells with β-catenin in the nucleus. These are first apparent at E10.5 (C) (white arrows indicate examples), becoming 
more pronounced at E12.5 (F) and E13.5 (K). (H) A higher magnification image, showing a typical example of nuclear β-cat-
enin at E12.5. All sections are coronal and dorsal is up. Scale bars (A, D) 250 μm; (B, C, E, F, J, K) 100 μm; (G, H) 5 μm.
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Activation of Wnt/β-catenin target gene expression
We next investigated the possibility that increased levels
of nuclear β-catenin in the mutant developing cerebral
cortex enhance the transcription of Wnt/β-catenin target
genes. The BAT-gal reporter transgene has seven fused Tcf/
Lef-binding sites regulating the expression of β-galactosi-
dase in response to β-catenin-specific activation [25]. We
crossed the BAT-gal reporter allele onto our control and
mutant animals in order to assess changes to β-catenin
transcriptional activity resulting from loss of Apc func-
tion. The cerebral cortex reveals more intense LacZ stain-
ing in the mutant compared to the control (Figure 8B and
8A, respectively). These results suggest an over-activation
of canonical Wnt/β-catenin signalling due to β-catenin
stabilisation in the mutant. We next used in situ hybridisa-
tion and immunohistchemstry to examine the expression
of endogenous genes Axin2 (conductin), Lef1, and c-myc,
which are known to be up-regulated in response to Wnt/
β-catenin signalling [43-45]. At E13.5 in controls, Axin2
and Lef1 are expressed most strongly in the medial dorsal
telencephalon in the vicinity of the cortical hem, with rel-
atively low levels of expression in the cerebral cortex itself
(Figure 8C, F). In mutants at the same stage, high-level
expression of Axin2 and Lef1 extends throughout the cer-
ebral cortex (Figure 8D, G). qRT-PCR showed that there
was an increase in levels of Axin2  transcripts in the
mutants to about 10-fold those of the control (Figure 8E).
At E13.5, immunostaining for c-myc shows that there is
no expression of c-myc in the control (Figure 8H),
whereas the mutant shows expression of this protein in
the cerebral cortex (Figure 8I). Although there have been
reports that the cell cycle regulator p21 is negatively regu-
lated by Wnt/β-catenin signalling in colorectal cells or cell
lines [46,47], we found that levels of p21 protein were
actually elevated in the mutant cerebral cortex (compare
Figure 5J and 5K). Levels of p21 have been found to
increase when apoptosis is induced in APC-deficient cell
lines [48] and increased apoptosis in our mutants (Figure
4) may be responsible for increased p21 levels. Alterna-
tively, p21 expression in the cerebral cortex may not be
regulated in the same way as in colorectal cells or cell
lines. In conclusion, cells in the mutant cerebral cortex
ectopically up-regulate the expression of genes known to
be responsive to Wnt/β-catenin signalling, consistent with
the idea that loss of Apc causes the activation of canonical
Wnt signalling.
Loss of Apc function causes cerebral cortical cells to adopt 
alternative fates
In the preceding section we demonstrate that loss of Apc
function results in increased nuclear β-catenin and aber-
rant activation of Wnt/β-catenin target gene expression in
the cerebral cortex. Wnt signalling is important for speci-
fying cell identity in the embryonic central nervous sys-
tem, so we next examined whether cerebral cortical cells
alter their identity following loss of Apc.
During its normal development, the cerebral cortex is
characterised by the expression of a number of transcrip-
tion factors. These include the winged helix transcription
factor Foxg1 [49,50], the homeodomain transcription fac-
tor Pax6 [51,52] and the T-box transcription factors Tbr1
and Tbr2 [30,53]. At E10.5, both control (Figure 9A) and
mutant (Figure 9B) cerebral cortex express Foxg1. In con-
trols, Foxg1 expression continues at later ages, with strong
expression seen in the cerebral cortex at E13.5 (Figure 9C)
and E15.5 (Figure 9E). In contrast, Foxg1 expression is
severely reduced in the mutant cerebral cortex at E13.5
(Figure 9D) and E15.5 (Figure 9F) while expression in the
mutant ventral telencephalon is unaffected. In controls at
E13.5 (Figure 10A, B) and E15.5 (Figure 10E, F), Pax6 is
expressed at high levels by cells in the ventricular zone of
the cerebral cortex. In mutant embryos at E13.5 (Figure
10C, D) and E15.5 (Figure 10G, H), there are many fewer
cells expressing Pax6. At E15.5, Tbr1 is expressed strongly
by early born cortical neurons in the cortical plate of con-
trol embryos (Figure 10I, J) and Tbr2 is expressed by cells
in the subventricular zone and cortical plate (Figure 10M,
N). In mutant embryos there are fewer Tbr1- and Tbr2-
expressing cells and these are scattered towards the ven-
tricular surface of the mutant cerebral cortex (Figure 10K,
L, O, P). Our finding that many cerebral cortical cells do
not express molecular markers normally characteristic of
this region prompted us to examine whether they may
have adopted alternative fates.
We next examined the expression of genes that are not
normally expressed in the developing telencephalon but
are expressed in more posterior-dorsal regions of the brain
where levels of Wnt/β-catenin signalling are normally
higher than in the cerebral cortex. We found that the tran-
scription factors Pax3 [54] and Wt1 [55] are expressed in
the developing cerebral cortex of mutant embryos (Figure
11C, D, G, H, J) but are not detected in control embryos
at the same ages (Figure 11A, B, E, F, I). We used qRT-PCR
to show that Wnt1 [56-58] transcripts are easily detectable
in mutant (but not in control) cerebral cortex at E13.5
(Figure 11P).
Cells in the mutant cerebral cortex exhibit gene expression
patterns normally diagnostic of elevated Wnt/β-catenin
signalling (Figure 8) in combination with reduced levels
of the transcription factor Foxg1 (Figure 9). These molec-
ular properties are characteristic of cells in the cortical
hem region and presumptive hippocampus of the medial
dorsal telencephalon [59-61], prompting us to speculate
that cells in the mutant cerebral cortex had adopted the
fate of this region. To test this hypothesis, we used in situ
hybridisation to examine the expression of Wnt2b, whichNeural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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Figure 8 (see legend on next page)
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is normally expressed at high levels in the cortical hem
region, and Wnt8b, which is normally expressed in the
cortical hem region with expression extending dorsally
into the presumptive hippocampus [59,62]. Contrary to
our hypothesis, we found that neither Wnt2b (compare
Figure 11K and 11L) nor Wnt8b (compare Figure 11M and
11N) were ectopically expressed in the mutant cerebral
cortex (compare staining intensity in the cerebral cortex to
that in the cortical hem/hippocampal region in Figure
11K–N). qRT-PCR on RNA extracted from control and
mutant dorsal telencephalon revealed a twofold increase
in Wnt8b expression (Figure 11O). As Wnt8b expression
had not extended into the mutant cerebral cortex, this
modest increase might be a local up-regulation of Wnt8b
expression within the cortical hem region or reflect the
reduced size of the mutant cerebral cortex relative to the
cortical hem region. The Emx1Cre allele we used to inacti-
vate Apc is not active in the cortical hem itself (Figure 1)
[33], so it is not surprising that the molecular characteris-
tics of the cortical hem are not affected in Apc mutants
(compare cortical hem region expression of Axin2  and
Lef1 expression in Figure 8 and Wnt2b and Wnt8b expres-
sion in Figure 11 between control and mutant embryos).
The mutant cerebral cortex does not, therefore, corre-
spond to a lateral expansion of cortical hem or hippocam-
pal identity.
The loss of Apc function therefore causes dorsal telen-
cephalic cells to adopt molecular characteristics normally
associated with more posterior-dorsal parts of the central
nervous system.
Shh signalling is not upregulated following loss of Apc
We next investigated the possibility that the disorganisa-
tion we observe in the Apc mutant cerebral cortex might
be a contributory factor to altering the molecular identity
of its cells. It has been reported that disrupting adherens
junctions in αE-catenin loss-of-function mutants results in
up-regulation of Shh signalling via a mechanism inde-
pendent of altered Wnt/β-catenin signalling [63,64]. As β-
catenin is a component of adherens junctions, the disreg-
ulation of β-catenin function in the Apc mutants could
conceivably produce disruption to normal adherens junc-
tions, causing up-regulation of Shh signalling, which
could in turn affect cell identity. The αE-catenin mutant
cerebral cortex shares some features in common with the
Apc mutant – for example, increased numbers of mitoses
away from the apical surface of the ventricular zone –
although they differ in other respects – for example, the
αE-catenin  mutant exhibits increased cell proliferation
whereas the Apc mutant does not. To test the possibility
that increased Shh signalling might be a contributory fac-
tor to our Apc mutant phenotype, we examined the expres-
sion of the Shh transcriptional targets, the transcription
factors Gli1 and Olig2, and the Shh receptor Ptc [65-69].
We found that expression of Gli1, Ptc and Olig2 in the cer-
ebral cortex at E13.5 is below our limits of detection in
both control and mutant cerebral cortex, and far below
the levels seen in the thalamus (compare Figure 12A, B, E
to 12C, D, H). This indicates that Shh signalling is not up-
regulated in the cerebral cortex following loss of Apc func-
tion. Shh signalling is associated with adoption of ventral
fate in the central nervous system and we used immuno-
histochemistry to examine expression of the ventrally
expressed transcription factors Islet1 and Mash1 [70-72].
We found no evidence for ectopic expression of these ven-
tral markers in the cerebral cortex of the mutant at E13.5
(compare Figure 12F, G to 12I, J). It is, therefore,
extremely unlikely that aberrant activation of Shh signal-
ling can explain the Apc cerebral cortical loss-of-function
phenotype.
Discussion and conclusion
In this study we have examined the consequences of
removing Apc protein from the developing mouse cere-
bral cortex after E9.5, an age by which it has already
acquired molecular characteristics of the cerebral cortex.
Apc is a multifunctional protein with roles in cell prolifer-
Altered expression of β-catenin  target genes in mutant cerebral cortex Figure 8 (see previous page)
Altered expression of β-catenin  target genes in mutant cerebral cortex.  (A, B) X-gal staining (blue) for beta-galac-
tosidase in the telencephalon of control (Emx1Cre/+Apc580S/+) and mutant (Emx1Cre/+Apc580S/580S) embryos at embryonic day 
(E)13.5 carrying the BAT-gal reporter transgene. X-gal staining in the cerebral cortex (cc) is less intense in the control (A) com-
pared to the mutant (B). Brown immunostaining in (A, B) is for β-galactosidase. (C, D, F, G) In situ hybridisation for Axin2 (C, 
D) and Lef1 (F, G) transcripts (dark staining) in control (C, F) and mutant (D, G) forebrain at E13.5 presented as greyscale 
images. In controls, Axin2 expression is highest in the cortical hem (red arrow in (C)) and Lef1 expression is highest just adja-
cent to the hem (red arrow in (F)). In the mutant, expression of both Axin2 and Lef1 is high throughout the cerebral cortex. 
(E) qRT-PCR showing a large increase in the levels of Axin2 transcripts in the E13.5 cerebral cortex of mutant compared to 
control embryos. P-value calculated using Student's t-test is indicated above the bars. Error bars are standard error of the 
mean. The ubiquitous pale staining in (C-G) is non-specific background. (H-K) Immunostaining for c-myc and p21 (brown) in 
the telencephalon of control (H, J) and mutant embryos (I, K) at E13.5. The control cerebral cortex is negative for c-myc stain-
ing, but the mutant cerebral cortex has c-myc positive cells. P21 levels are also increased in the mutant. All sections are coro-
nal and dorsal is up. Additional abbreviations: t, thalamus. Scale bars: (A, B) 400 μm; (C-G) 200 μm; (H-K) 100 μm.Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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Foxg1 expression (brown) in the telencephalon of control and mutant embryos at embryonic day (E)10.5, E13.5, and E15.5 Figure 9
Foxg1 expression (brown) in the telencephalon of control and mutant embryos at embryonic day (E)10.5, 
E13.5, and E15.5. (A, B) E10.5 telencephalons of the control and the mutant have a similar pattern of expression in the 
future cerebral cortex (cc) and ventral telencephalon (vtel). (C, D) By E13.5 control (C) embryos retain expression in the cer-
ebral cortex while mutants (D) exhibit very low levels of cerebral cortex expression, although expression in the ventral telen-
cephalon is unaffected. (E, F) At E15.5, control embryos (E) expresses Foxg1 throughout the cerebral cortex whereas the 
mutant (F) has very low expression of Foxg1 in the cerebral cortex, although expression in the ventral telencephalon is unaf-
fected. All sections are coronal, except (E, F), which are parasagittal, and dorsal is up. Scale bars: (A, B) 100 μm; (C-D) 200 μm.
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Figure 10 (see legend on next page)
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ation, differentiation, migration, and apoptosis [73], so it
is perhaps not surprising that we find disruption of a mul-
titude of developmental processes in Apc  mutants.
Disruption to β-catenin function in the Apc mutant
It is likely that many of the defects observed in condi-
tional Apc mutants stem from a disregulation of β-catenin
function, although loss of Apc function may also have
consequences independent of β-catenin. The earliest
abnormality we detected was an increase in nuclear β-cat-
enin at E10.5 followed by up-regulation in the expression
of β-catenin/TCF/Lef transcriptional targets, including the
BAT-gal reporter transgene and endogenous targets c-myc,
Lef1 and Axin2. A key role of Apc is to mediate the destruc-
tion of β-catenin, a process that is blocked when the cell
receives a Wnt signal [17]. Loss of Apc function might,
therefore, be expected to produce similar effects to Wnt
signalling and/or β-catenin stabilisation. Transgenic mice
in which a stabilised β-catenin mutant protein was
expressed in central nervous system progenitor cells under
the control of a nestin promoter had shown dramatically
enlarged cerebral cortex surface area, although lamination
was not affected [74,75]. Increased brain size was
explained by expansion of the progenitor pool due to cells
re-entering the cell cycle instead of differentiating. In con-
trast, our Apc mutants exhibit a massive reduction in the
size of the cerebral cortex, resulting from a combination of
reduced proliferative pool size and increased cell death by
apoptosis, and lamination is disrupted. These differences
can likely be explained by differences in the timing of β-
catenin stabilisation since the timing of Wnt/β-catenin
signalling is known to be critical for neural cell fate deci-
sions, and stabilising β-catenin during early cerebral corti-
cal development promotes proliferation while at later
stages it promotes neural differentiation [76-80]. The nes-
tin promoter used by Chenn and Walsh results in expres-
sion of stabilised β-catenin in neural precursors [81]
before they become committed to a cerebral cortical fate
and start to express Emx1 at E9.5, whereas in our model
nuclear β-catenin is first detected at E10.5 after the onset
of Emx1 expression.
The magnitude of Wnt/β-catenin signalling experienced
by cells is tightly regulated during development by the
combined action of Wnt proteins and their antagonists. A
number of Wnt proteins are secreted by cells in the cere-
bral cortex and by the cortical hem in the medial telen-
cephalon [59,82]. Wnt antagonists – for example, Sfrp
and Dickkopf proteins – are expressed in complex spatio-
temporal patterns during cerebral cortical development
[83-87]. By disrupting Apc we short-circuited these regula-
tory mechanisms as β-catenin is stabilised, and translo-
cated to the nucleus, regardless of the presence of a Wnt
signal. This results in the expression of Wnt/β-catenin tar-
get genes at higher levels than normally experienced by
cerebral cortical cells. The severe consequences for cere-
bral cortical development emphasise the importance of
maintaining the correct levels of Wnt/β-catenin signalling
for the acquisition of the correct fate by cells in the devel-
oping cerebral cortex. One of our major findings is that
many cells in the Apc mutant stop expressing genes nor-
mally expressed by cerebral cortex and start to express
genes normally expressed elsewhere, indicating altered
identity (see below). Critically, these changes occur after
the cerebral cortex has become committed to its fate as Apc
is inactivated after the expression of Emx1. Our results
indicate, therefore, that acquisition of cerebral cortical
neural fates is reversible. An interesting possibility is that
Apc is required to stabilise the acquisition of cerebral cor-
tical cell fates and that loss of Apc allows cells to redirect
to alternative fates.
Apc and cell polarity
A striking feature of Apc mutants is the disorganisation of
the cerebral cortex. In wild-type embryos the nuclei of
cells undergoing M-phase line up along the ventricular
surface and then travel deeper into the ventricular zone
before entering S-phase. When Apc is inactivated the
molecular and cellular properties of the ventricular zone
are severely affected. Pericentrin, β-catenin, and N-cad-
herin proteins are normally concentrated at the apical sur-
face of the ventricular zone and this normally polarised
organisation is lost in the Apc mutants. The normal posi-
tioning of M-phase nuclei at the apical surface and S-
Pax6, Tbr1, and Tbr2 expression in the cerebral cortex of control and mutant embryos Figure 10 (see previous page)
Pax6, Tbr1, and Tbr2 expression in the cerebral cortex of control and mutant embryos. (A-H) Pax6 immunohis-
tochemistry of embryonic day (E)13.5 (A-D) and E15.5 brains (E-H). Expression of Pax6 is lower in the mutant both at E13.5 
(C, D) and E15.5 (G, H) compared to control (A, B and E, F). (I-L) Expression pattern of Tbr1 (brown) in control and mutant 
embryos at E15.5. (I, J) In controls, Tbr1 is expressed in a laminar pattern in the cortical plate. (K, L) In the mutant, Tbr1 
expression is reduced, with expressing cells concentrated at the ventricular surface. (M-P) Expression pattern of Tbr2 in con-
traol and mutant embryos at E15.5. (M, N) In controls, Tbr2 (brown) is expressed in a laminar pattern in the subventricular 
zone and in the cortical plate. (O, P) In the mutant, Tbr2 expression is reduced with expressing cells concentrated at the ven-
tricular surface. Boxed areas in (A, C, E, G, I, K, M, O) are shown at higher magnification in (B, D, F, H, J, L, N, P). All sections 
are coronal and dorsal is up. Scale bars: (A, C, E, G) are to same scale with bar in (G) 200 μm; (I, K, M, O) are to same scale 
with bar in (O) 400 μm; (B, D, F, H, J, L, N, P) are to same scale with bar in (P) 100 μm.Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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Figure 11 (see legend on next page)
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phase nuclei away from the apical surface is lost in the
mutants. This suggests that Apc is required for the estab-
lishment or maintenance of apical identity and indeed we
observed particularly high levels of Apc protein at the api-
cal surface of the ventricular zone from E11.5 to E14.5.
Apc might function by polarising the response to Wnt sig-
nalling within the cell and/or by tethering proteins
(including pericentrin, β-catenin, and N-cadherin) and
regulating their polarised distribution within the cell. N-
cadherin is a cell adhesion molecule that functions by
coupling to the cytoplasmic catenin proteins (including β-
catenin). Developing cerebral cortex lacking N-cadherin
[88] exhibits many defects that resemble those seen when
Apc  is inactivated (present study), including disrupted
interkinetic nuclear migration, loss of cell polarity, and
disorganisation of cerebral cortical layers. A conditional β-
catenin loss of function mutant [80] also exhibited dis-
rupted interkinetic nuclear migration and cerebral cortical
disorganisation reminiscent of both our Apc mutant and
the N-cadherin mutant. This provides support for the
hypothesis that Apc, β-catenin, and N-cadherin co-operate
genetically during normal cerebral cortical development
and that loss of Apc function causes loss of N-cadherin
and β-catenin functions. Mechanistically, this could occur
at the level of disruption to cytoskeletal protein interac-
tions and/or by means of altered gene expression in the
Apc mutant. In the developing limb bud, nuclear β-cat-
enin down-regulates expression of cadherin [89] and the
altered N-cadherin distribution seen in our mutant could
be caused by a down-regulation in gene expression caused
by elevated levels of nuclear β-catenin.
Apc and cell identity
The position of cells in the developing cerebral cortex is
normally tightly regulated and it is possible that the fail-
ure of cells to adopt their correct positions in the Apc
mutant might affect their molecular environment and this
might cause them to adopt alternative fates. It has recently
been shown that conditional deletion of the small Rho-
GTPase cdc42 in the developing cerebral cortex disrupts
interkinetic nuclear migration and cell polarity, with
fewer cells undergoing mitosis at the apical surface of the
ventricular zone [90]. The corresponding increase in
basally located mitosis correlates with an increase in the
number of cells acquiring the fate of basal progenitors and
expressing the transcription factor Tbr2. Although the
cdc42 mutant resembles our Apc mutant with respect to
the shift in balance from apical to basal mitosis, we actu-
ally see a decrease in the numbers of Tbr2 expressing cells
(Figure 10). Executing mitosis away from the ventricular
surface in Apc mutants is, therefore, not sufficient to direct
cells to a basal cerebral cortical Tbr2 expressing fate. The
Apc mutant is not the simplest model in which to study
correlations between basal mitosis and post-mitotic Tbr2
expression as the loss of cerebral cortical identity found in
Apc mutants might independently contribute to the reduc-
tion in the numbers of cells expressing Tbr2. It is
extremely unlikely that the alterations to cell identity in
the Apc mutant stem from an ectopic upregualtion of the
Shh pathway as cells in the Apc mutant cerebral cortex do
not ectopically express the Shh target genes Gli1, Ptc, or
Olig2.
There is accumulating evidence that high levels of Wnt/β-
catenin signalling during early vertebrate development
promote posterior neural cell fates at the expense of ante-
rior neural cell fates and that the formation of anterior
head structures requires the active suppression of Wnt/β-
catenin signalling [91-94]. Wnt/β-catenin signalling is
also tightly regulated along the dorsal-ventral axis such
that higher levels of Wnt/β-catenin activity generally map
to dorsal central nervous system structures [25].
Expression of Pax3, Wt1, Wnt2b, Wnt8b, and Wnt1 in the developing cerebral cortex of control and mutant embryos Figure 11 (see previous page)
Expression of Pax3, Wt1, Wnt2b, Wnt8b, and Wnt1 in the developing cerebral cortex of control and mutant 
embryos. (A-H) Pax3 immunostaining in control (A, B, E, F) and mutant (C, D, G, H) embryos at embryonic day (E)12.5 (A-
D) and E15.5 (E-H). At E12.5, Pax3 positive cells are present in the epithalamus of the control (A, black arrow) and the mutant 
(D, black arrow). The control cortex is free of Pax3 expression (B). There are a few Pax3 positive cells in the mutant cerebral 
cortex (D, black arrow). At E15.5, there is no expression of Pax3 by the control cortex (E, F). Pax3 expression is increased in 
the mutant cerebral cortex (G, H) and Pax3 immunopositive cells are located in upper layers of the cerebral cortex (H). (I, J) 
Immunostaining for Wt1 (red) in control (I) and mutant embryos (J) at E12.5. Wt1 expression is only seen in the mutant. (K-
N) In situ hybridisation for Wnt2b (K, L) and Wnt8b (M, N) transcripts (dark staining) presented as greyscale images in control 
(K, M) and mutant forebrain (L, N) at E13.5. In control embryos, Wnt2b (K) and Wnt8b (M) expressionis largely restricted to 
the cortical hem region, with Wnt8b expression extending more dorsally into the medial telencephalon (red arrows). In mutant 
embryos, Wnt2b (L) and Wnt8b (N) expression is similarly restricted (red arrows) and does not extend into the cerebral cor-
tex. The ubiquitous pale staining is non-specific background. (O, P) qRT-PCR of RNA extracted from E13.5 cerebral cortex of 
mutant compared to control embryos showing a modest increase in the levels of Wnt8b (O) and a massive increase in the lev-
els of Wnt1 transcripts (P) relative to GAPDH. Student's t-test p-values are indicated above the bars. Error bars are standard 
error of the mean. All sections are coronal and dorsal is up. Abbreviations: cc, cerebral cortex. Scale bars: (A, C) 200 μm; (B, 
D, I, J) 50 μm; (E, G) 400 μm; (K-N) 200 μm.Neural Development 2009, 4:3 http://www.neuraldevelopment.com/content/4/1/3
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Expression of Gli1, Ptc, Olig2, Islet1, and Mash1 in the forebrain of control and mutant embryos at embryonic day (E)13.5 Figure 12
Expression of Gli1, Ptc, Olig2, Islet1, and Mash1 in the forebrain of control and mutant embryos at embryonic 
day (E)13.5. (A-D) In situ hybridisation for Gli1 (A, C) and Ptc (B, D) transcripts (dark staining) in control (A, B) and mutant 
(C, D) presented as greyscale images. Gli1 and Ptc are expressed at similarly low levels in the cerebral cortex (cc) of control 
embryos and mutant embryos. Both transcripts are expressed at similarly high levels in the thalamus (t) of control and mutant 
embryos. The ubiquitous pale staining is non-specific background. (E-J) Immunohistochemistry for Olig2 (E, H), Islet1 (F, I), and 
Mash1 (G, J) proteins (brown) in control (E-G) and mutant forebrain (H-J) at E13.5. In both control and mutant embryos, 
Olig2, Islet1, and Mash1 are strongly expressed in ventral telencephalic (vtel) domains but not in the cerebral cortex. All 
images to same scale, bar in (J) 200 μm.
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The failure of the Apc mutant cerebral cortex to express
transcription factors Pax6, Foxg1, Tbr1, and Tbr2 indicates
that they lose their cerebral cortical identity, raising the
question of what identity they acquire. One possibility is
that ectopic activation of Wnt/β-catenin signalling in the
cerebral cortex of the Apc mutant might redirect cerebral
cortical cells to adopt fates normally associated with more
posterior-dorsal central nervous system structures (such as
dorsal diencephalon, dorsal midbrain, dorsal hindbrain
and dorsal spinal cord) where Wnt/β-catenin signalling is
high. To test this hypothesis, we examined the expression
of three genes (Pax3, Wnt1, and Wt1) normally expressed
in posterior/dorsal brain structures. Pax3 is normally
expressed dorsally in the epithalamus, in the ventricular
zone at the mesencephalic-rhombencephalic border, in
the dorsal part of the ventricular zone and the roof plate
of the medulla oblongata, and the dorsal spinal cord
[54,95]. Wnt1 expression is normally restricted to the dor-
sal and ventral midline of the midbrain and caudal dien-
cephalons, a narrow ring rostral to the midbrain-
hindbrain junction and the roof plate of the spinal cord
[56-58]. The transcription factor Pax3 can regulate the
expression of Wnt1 by binding to DNA sequences in its
promoter [96], which may account for the similarities in
their expression domains. Wt1 is normally expressed in
the roofplate of the midbrain and in the spinal cord [55].
Conversely, Gli1, Ptc, Mash1, Olig2, and Islet1 are normally
expressed in ventral regions of the central nervous system
where Wnt/β-catenin signalling is generally low [25]. Our
finding that ectopic expression of Pax3, Wnt1, and Wt1,
but not Gli1, Ptc, Mash1, Olig2, or Islet1, occurs in the Apc
mutant cerebral cortex is consistent with the idea that loss
of Apc simulates enhanced Wnt/β-catenin signalling and
pushes cerebral cortical cells towards posterior-dorsal, but
not ventral, fates. Following this reasoning, it might be
predicted that the Apc  mutant cerebral cortex would
ectopically express molecular characteristics of the cortical
hem region and presumptive hippocampus, dorsal-
medial telencephalic structures adjacent to the cerebral
cortex and characterised by high levels of Wnt/β-catenin
signalling and expression of Wnt genes, including Wnt2b
and Wnt8b and low expression of Foxg1 [25,59,60]. How-
ever, we found no ectopic expression of Wnt2b or Wnt8b
in the Apc mutant cerebral cortex, raising the possibility
that some factor in the cerebral cortex in the Apc mutant
somehow protects it from lateral to medial re-patterning
and acquiring cortical hem region identity. Foxg1 [50,60]
is a good candidate for this factor. Conditional Foxg1
mutants in which Foxg1  is deleted after E13.5 do not
exhibit an enlarged cortical hem region [97,98], although
Foxg1-/-  null embryos do exhibit large scale lateral to
medial re-patterning of the telencephalon [61]. Our Apc
mutants express Foxg1 normally at E10.5 but subse-
quently lose expression in the cerebral cortex with almost
none left at E13.5. One possibility, therefore, is that early
expression of Foxg1 is sufficient to prevent the acquisition
of dorsal-medial telencephalic fate by the more lateral cer-
ebral cortex. Other possibilities are that the levels of β-cat-
enin transcriptional activation in our mutants are not
appropriate to specify cortical hem region identity on the
cerebral cortex or that there is a requirement for Apc itself
in this process.
Apc and cell differentiation
The activation of Wnt/β-catenin mediated gene expres-
sion varies during the division and maturation of cerebral
cortical cells [20]. Proliferating cells in the ventricular
zone exhibit high levels of β-catenin signalling, which is
down-regulated as they exit the cell cycle and start their
radial migration to the cortical plate and then up-regu-
lated as they reach their destinations in the cortical plate
[20]. Loss- and gain-of-function experiments have identi-
fied roles for β-catenin in neuronal differentiation as well
as proliferation [20,76-80]. In this study we identified an
up-regulation of Apc/Apc during the early development of
the cerebral cortex that coincides with increasing numbers
of post-mitotic cortical plate cells expressing high levels of
Apc. This raised the possibility that Apc is required for the
proper differentiation of cells within the cortical plate.
Consistent with this idea, we showed that the transcrip-
tion factors Tbr1 and Tbr2 do not exhibit their normal
laminar distribution in the Apc mutant cerebral cortex.
The failure of mutant cells to occupy their normal loca-
tions indicates defects in cell adhesion or migration con-
sistent with previously described roles for Apc [99,100].
We found that the Apc mutant cerebral cortex has lost
many aspects of its molecular identity by E13.5. The
severe disruption to multiple aspects of cerebral cortical
development we see in Apc mutants by E13.5 makes it dif-
ficult to address the primary function(s) of Apc in the dif-
ferentiation of more mature cell types generated at later
stages because it becomes increasingly difficult to disen-
tangle the primary consequences of Apc disruption from
the secondary consequences of major tissue insult and re-
specification. In order to directly address the primary
functions of Apc in the differentiation of cerebral cortical
cells, it will be necessary to manipulate Apc function in
these cells at later stages of development than in the cur-
rent Emx1Cre/+Apc580S/580S transgenic model.
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